Contact
searchSearch
HMP Global

Multiple Myeloma Topic Center

Featured Article

Usmani Headshot
Conference Coverage
Rethinking the Risk: Evolving Strategies for High-Risk Smoldering Myeloma at SOHO 2025
09/08/2025
Saad Z. Usmani, MD, FACP
Dr Saad Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, explores the evolving debate on early intervention for high-risk smoldering multiple myeloma, highlighting pivotal trial data and its potential to reshape...
Dr Saad Usmani, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, explores the evolving debate on early intervention for high-risk smoldering multiple myeloma, highlighting pivotal trial data and its potential to reshape...
Dr Saad Usmani, chief of the...
09/08/2025
First Report Managed Care
Martin
Conference Coverage
What’s Next in Multiple Myeloma: Smoldering, High-Risk, and Frontline Therapy
09/03/2025
Thomas G. Martin, III, MD
Dr Thomas Martin previews his SOHO 2025 session and explores the pressing next questions in multiple myeloma, including when to treat smoldering disease, how to better define and manage high-risk patients, and how innovations like bispecifics...
Dr Thomas Martin previews his SOHO 2025 session and explores the pressing next questions in multiple myeloma, including when to treat smoldering disease, how to better define and manage high-risk patients, and how innovations like bispecifics...
Dr Thomas Martin previews his...
09/03/2025
First Report Managed Care
Raje Headshot
Conference Coverage
CAR T-Cell Therapy in Myeloma: A New Era of Early Intervention
09/02/2025
Noopur S. Raje, MD
At SOHO 2025, Dr Noopur Raje will present a cutting-edge overview of CAR T-cell therapy in multiple myeloma, highlighting long-term efficacy data, novel targets like GPRC5D, emerging dual-targeting and in vivo CAR strategies, and the evolving...
At SOHO 2025, Dr Noopur Raje will present a cutting-edge overview of CAR T-cell therapy in multiple myeloma, highlighting long-term efficacy data, novel targets like GPRC5D, emerging dual-targeting and in vivo CAR strategies, and the evolving...
At SOHO 2025, Dr Noopur Raje...
09/02/2025
First Report Managed Care
News
DKRd Induction Yields Superior MRD Negativity in NDMM, Regardless of Transplant
07/23/2025
Grace Taylor, MS, MA
The ADVANCE trial shows that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (KRd) significantly improves minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma, according to a study presented at the 2025...
The ADVANCE trial shows that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (KRd) significantly improves minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma, according to a study presented at the 2025...
The ADVANCE trial shows that...
07/23/2025
First Report Managed Care
News
Peripheral Residual Disease Monitoring Signals Progression Risk in Multiple Myeloma
10/18/2024
Jolynn Tumolo
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease...
10/18/2024
First Report Managed Care
Dimopoulos
Conference Coverage
Advancing Treatment Options for High-Risk Multiple Myeloma
10/02/2024
Meletios-Athanasios Dimopoulos
Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.
Discover how the addition of daratumumab to standard treatment improves outcomes for patients with high-risk cytogenetic abnormalities in multiple myeloma according to a SOHO 2024 presenter.
Discover how the addition of...
10/02/2024
First Report Managed Care
Conference Insider
Early Data Show Fast, Deep Responses With Teclistamab-Based Regimen for Multiple Myeloma
04/13/2023
Maria Asimopoulos
Emma Searle, MD, PhD, reviews early data from MajesTEC-2, a trial designed to evaluate the recently approved monoclonal antibody teclistamab in combination with daratumumab and lenalidomide in patients with relapsed/refractory multiple...
Emma Searle, MD, PhD, reviews early data from MajesTEC-2, a trial designed to evaluate the recently approved monoclonal antibody teclistamab in combination with daratumumab and lenalidomide in patients with relapsed/refractory multiple...
Emma Searle, MD, PhD, reviews...
04/13/2023
First Report Managed Care
Conference Coverage
Oral, IV Multiple Myeloma Therapy Start Rates Significantly Increased During Pandemic
03/28/2023
Hannah Musick
Researchers speculated the increased therapy initiation rates may be explained by a significant decrease in the number of newly diagnosed patients.
Researchers speculated the increased therapy initiation rates may be explained by a significant decrease in the number of newly diagnosed patients.
Researchers speculated the...
03/28/2023
First Report Managed Care
Headshot of Dr Hira Shaikh, University of Iowa
Interview
Hispanic Ethnicity Associated With Worse Multiple Myeloma Outcomes, Study Shows
01/19/2023
Maria Asimopoulos
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant...
01/19/2023
First Report Managed Care
News
Combination Therapy for Multiple Myeloma Emerging as Standard of Care
12/22/2022
Edan Stanley
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy...
12/22/2022
First Report Managed Care
News
Stem Cell Yield Adequate for Transplant After 4 Cycles of Daratumumab, Lenalidomide Quadruplet Induction for MM
12/21/2022
Jolynn Tumolo
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from...
12/21/2022
First Report Managed Care

Newsfeed

News
DKRd Induction Yields Superior MRD Negativity in NDMM, Regardless of Transplant
07/23/2025
Grace Taylor, MS, MA
The ADVANCE trial shows that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (KRd) significantly improves minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma, according to a study presented at the 2025...
The ADVANCE trial shows that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (KRd) significantly improves minimal residual disease (MRD) negativity in newly diagnosed multiple myeloma, according to a study presented at the 2025...
The ADVANCE trial shows that...
07/23/2025
First Report Managed Care
News
Peripheral Residual Disease Monitoring Signals Progression Risk in Multiple Myeloma
10/18/2024
Jolynn Tumolo
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease identified using next-generation flow in patients with transplant-eligible multiple myeloma was associated with a 13-fold increased risk of progression or death, according to a clinical trial update published...
Peripheral residual disease...
10/18/2024
First Report Managed Care
News
Combination Therapy for Multiple Myeloma Emerging as Standard of Care
12/22/2022
Edan Stanley
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy and safety data from the phase 3 CANDOR study in which patients with relapsed or refractory multiple myeloma were treated with two combination therapy options.
Authors shared updated efficacy...
12/22/2022
First Report Managed Care
News
Stem Cell Yield Adequate for Transplant After 4 Cycles of Daratumumab, Lenalidomide Quadruplet Induction for MM
12/21/2022
Jolynn Tumolo
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from the MASTER and GRIFFIN trials to determine whether patients could undergo stem cell transplants after receiving induction therapy that included daratumumab and lenolidamide. 
Researchers reviewed data from...
12/21/2022
First Report Managed Care
News
Real-World Treatment Patterns, Outcomes in Patients With Double- and Triple-Class R/R Multiple Myeloma
12/15/2022
Jolynn Tumolo
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily pretreated patient population to determine which drugs were being administered, as well as their impact on overall survival.
Researchers studied a heavily...
12/15/2022
First Report Managed Care
News
Combination Regimen Prolongs Overall Survival in Relapsed/Refractory Multiple Myeloma
12/08/2022
Jolynn Tumolo
The study participants received up to 8 cycles of bortezomib and dexamethasone, with or without daratumumab, until disease progression.
The study participants received up to 8 cycles of bortezomib and dexamethasone, with or without daratumumab, until disease progression.
The study participants received...
12/08/2022
First Report Managed Care
News
Comparing Cost-Effectiveness of 3 Treatment Regimens for Multiple Myeloma
12/29/2021
Maria Asimopoulos
Combination lenalidomide plus dexamethasone was more cost-effective than 2 other treatment regimens in patients with multiple myeloma, though authors encouraged further analyses that include overall survival data.
Combination lenalidomide plus dexamethasone was more cost-effective than 2 other treatment regimens in patients with multiple myeloma, though authors encouraged further analyses that include overall survival data.
Combination lenalidomide plus...
12/29/2021
First Report Managed Care
News
Novel Multiple Myeloma Agents Can Add Years, but at High Costs
12/22/2021
Jolynn Tumolo
Researchers conducted a systematic review of multiple myeloma treatment options to "provide physicians, payers, and policy makers with the necessary information for evidence-based decision making to ensure accessibility to promising novel...
Researchers conducted a systematic review of multiple myeloma treatment options to "provide physicians, payers, and policy makers with the necessary information for evidence-based decision making to ensure accessibility to promising novel...
Researchers conducted a...
12/22/2021
First Report Managed Care
News
Triple Regimen for Relapsed/Refractory Multiple Myeloma Feasible in Frail Patients
12/15/2021
Jolynn Tumolo
A combination therapy demonstrated efficacy in frail older adults with relapsed/refractory multiple myeloma who had already received two or more therapies.
A combination therapy demonstrated efficacy in frail older adults with relapsed/refractory multiple myeloma who had already received two or more therapies.
A combination therapy...
12/15/2021
First Report Managed Care
News
Risk Factors Associated With Secondary Extramedullary Multiple Myeloma Development
12/08/2021
Jolynn Tumolo
Younger age, extensive bone disease, and other factors were linked to an increased risk of developing secondary extramedullary multiple myeloma, according to findings published online ahead of print.
Younger age, extensive bone disease, and other factors were linked to an increased risk of developing secondary extramedullary multiple myeloma, according to findings published online ahead of print.
Younger age, extensive bone...
12/08/2021
First Report Managed Care
News
Balancing Clinical Outcomes and Cost: The Value of Biosimilars in Retinal Disease Management
09/26/2025
Juliet Gallagher
A recent study examining the impact of retinal diseases highlights their significant clinical, social, and economic burden.
A recent study examining the impact of retinal diseases highlights their significant clinical, social, and economic burden.
A recent study examining the...
09/26/2025
First Report Managed Care
News
Trump Administration to Test AI-Powered Prior Authorization in Medicare
09/25/2025
Grace Taylor, MS, MA
The Trump administration is set to launch a decade-long Medicare pilot that uses artificial intelligence (AI)-driven prior authorization to curb costs, sparking bipartisan concern over access to care and patient safety.
The Trump administration is set to launch a decade-long Medicare pilot that uses artificial intelligence (AI)-driven prior authorization to curb costs, sparking bipartisan concern over access to care and patient safety.
The Trump administration is set...
09/25/2025
First Report Managed Care
News
Policy Impact: FDA’s Interchangeability Designation Expands Biosimilar Access
09/25/2025
Juliet Gallagher
Insulin glargine, marketed as Semglee and its biosimilar insulin glargine-yfgn, was granted interchangeable status, allowing pharmacists to substitute it for the branded originator without requiring prescriber intervention. A new economic...
Insulin glargine, marketed as Semglee and its biosimilar insulin glargine-yfgn, was granted interchangeable status, allowing pharmacists to substitute it for the branded originator without requiring prescriber intervention. A new economic...
Insulin glargine, marketed as...
09/25/2025
First Report Managed Care
News
How Timing Shapes Biosimilar Success: Insights from US Market Data
09/24/2025
Juliet Gallagher
A recent study published in Value in Health sheds light on the competitive dynamics of biosimilar drugs in the US, specifically examining whether first-mover advantages resemble those seen in generic drug markets.
A recent study published in Value in Health sheds light on the competitive dynamics of biosimilar drugs in the US, specifically examining whether first-mover advantages resemble those seen in generic drug markets.
A recent study published in...
09/24/2025
First Report Managed Care
Hero Image
News
‘First Report Managed Care’ Webinar to Address Specialty Pharmacy Disruption, Cost Pressures, and Patient Access
09/24/2025
Danielle Sposato
Rising specialty drug costs, surging demand for GLP-1 therapies, and ongoing supply chain and policy challenges are putting patient access at risk. To address these pressures, First Report Managed Care will host a complimentary 60-minute...
Rising specialty drug costs, surging demand for GLP-1 therapies, and ongoing supply chain and policy challenges are putting patient access at risk. To address these pressures, First Report Managed Care will host a complimentary 60-minute...
Rising specialty drug costs,...
09/24/2025
First Report Managed Care
News
Biosimilars Match Humira in Structure, Show Greater Stability Under Real-World Stress
09/22/2025
Juliet Gallagher
A new analytical study underscores how advanced nuclear magnetic resonance (NMR) spectroscopy can sharpen head-to-head comparisons between Humira (adalimumab) and its biosimilars—particularly when products are challenged under real-world...
A new analytical study underscores how advanced nuclear magnetic resonance (NMR) spectroscopy can sharpen head-to-head comparisons between Humira (adalimumab) and its biosimilars—particularly when products are challenged under real-world...
A new analytical study...
09/22/2025
First Report Managed Care
News
$3.2 Million Saved Through Biosimilar Substitution in Rheumatology Clinics
09/19/2025
Juliet Gallagher
A study published in the Journal of Clinical Rheumatology found that a recent initiative at a large academic medical center significantly increased biosimilar uptake and generated substantial cost savings through targeted interventions.
A study published in the Journal of Clinical Rheumatology found that a recent initiative at a large academic medical center significantly increased biosimilar uptake and generated substantial cost savings through targeted interventions.
A study published in the Journal...
09/19/2025
First Report Managed Care
News
Pharmacists Lead, Physicians Lag? Provider Perspectives on Biosimilars and Interchangeability
09/18/2025
Juliet Gallagher
A new cross-sectional survey of 249 US outpatient clinicians—150 physicians and 99 pharmacists who treat immunologic conditions—offers a timely snapshot of how front-line decision-makers view biosimilars and the US Food and Drug...
A new cross-sectional survey of 249 US outpatient clinicians—150 physicians and 99 pharmacists who treat immunologic conditions—offers a timely snapshot of how front-line decision-makers view biosimilars and the US Food and Drug...
A new cross-sectional survey of...
09/18/2025
First Report Managed Care
News
Payer-Driven Biosimilar Preferences Create Financial and Operational Strain for Health Systems
09/17/2025
Juliet Gallagher
The expansion of US Food and Drug Administration (FDA)-approved biosimilars has been heralded as a major advancement for lowering healthcare costs in the US, with the potential to reduce both system-wide expenditures and patient out-of-pocket...
The expansion of US Food and Drug Administration (FDA)-approved biosimilars has been heralded as a major advancement for lowering healthcare costs in the US, with the potential to reduce both system-wide expenditures and patient out-of-pocket...
The expansion of US Food and...
09/17/2025
First Report Managed Care
News
DTX101 Gene Therapy Ends Development, Offers Key Lessons for Future Hemophilia B Treatment Strategies
09/16/2025
Grace Taylor, MS, MA
Early-phase trials of the DTX101 gene therapy in hemophilia B showed manageable safety but insufficient efficacy, leading to program discontinuation while offering critical insights for future gene therapy development.
Early-phase trials of the DTX101 gene therapy in hemophilia B showed manageable safety but insufficient efficacy, leading to program discontinuation while offering critical insights for future gene therapy development.
Early-phase trials of the DTX101...
09/16/2025
First Report Managed Care

Insights

Headshot of Dr Hira Shaikh, University of Iowa
Interview
Hispanic Ethnicity Associated With Worse Multiple Myeloma Outcomes, Study Shows
01/19/2023
Maria Asimopoulos
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant professor of hematology, oncology, and bone marrow transplant, University of Iowa Hospitals and Clinics, walks through the details of her study which compared multiple myeloma survival outcomes among Hispanic vs...
Hira Shaikh, MD, assistant...
01/19/2023
First Report Managed Care
Headshot of Joshua Richter, MD, Mount Sinai
Interview
Analyzing First-line Therapy for Multiple Myeloma: Real-World Data Differs From Trials
10/18/2022
Maria Asimopoulos
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate professor of medicine, hematology, and oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, reviews real-world data presented at the SOHO 2022 Annual Meeting in which combination bortezomib,...
Joshua Richter, MD, associate...
10/18/2022
First Report Managed Care

Behind the Bill

Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care
BEHIND THE BILL
When Agencies Lose Power: How 3 Seismic Shifts are Transforming Pharmaceutical Regulation
05/07/2025
Katie Hayes, MJ
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months, the landscape of administrative law has undergone a transformation so profound that pharmaceutical executives, health care providers, and patients alike are struggling to navigate the new terrain. The Supreme...
In the span of just 9 months,...
05/07/2025
First Report Managed Care
Behind the Bill
The Medicare Paradox, Part 3: Strategic Trade Doesn’t Have to be a Zero-Sum Game
05/07/2025
Katie Hayes, MJ
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve examined the growing friction between the Section 232 pharmaceutical tariff investigations and the Medicare drug pricing reforms authorized by the Inflation Reduction Act (IRA). These 2 policy agendas—industrial...
Over the past 2 weeks, I’ve...
05/07/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

News
Growth of Digital Therapeutics Requires Collaboration Among Key Players
10/06/2023
Jolynn Tumolo
The rapidly expanding field of digital therapeutics would likely benefit from international collaboration among manufacturers, government regulatory agencies, and researchers, according to a study published in NPJ Digital Medicine.
The rapidly expanding field of digital therapeutics would likely benefit from international collaboration among manufacturers, government regulatory agencies, and researchers, according to a study published in NPJ Digital Medicine.
The rapidly expanding field of...
10/06/2023
First Report Managed Care
News
Aflibercept May Improve Anatomic Progression in Nonproliferative Diabetic Retinopathy, But Not Visual Acuity
10/26/2023
Hannah Musick
“Aflibercept as a preventive strategy, as used in this trial, may not be generally warranted for patients with NPDR without CI-DME,” said researchers.
“Aflibercept as a preventive strategy, as used in this trial, may not be generally warranted for patients with NPDR without CI-DME,” said researchers.
“Aflibercept as a preventive...
10/26/2023
First Report Managed Care
Commentary
Why Better Lab Management Is Key to Value-Based Care
11/16/2023
Benion S. Horton, MD, MHA; Michael G. Lemieux, PhD
The health care community needs another tool to support its efforts to improve care while still managing testing use and costs. Lab benefit managers (LBMs) can provide the expertise to ensure the right tests are ordered at the right times to...
The health care community needs another tool to support its efforts to improve care while still managing testing use and costs. Lab benefit managers (LBMs) can provide the expertise to ensure the right tests are ordered at the right times to...
The health care community needs...
11/16/2023
First Report Managed Care
News
Targeted Medicine and Biological Therapies Fighting Type 2 Inflammation in Patients With Asthma
12/20/2023
Emry Lloyd
In a recent review, Imran Howell, University of Oxford, UK, and colleagues sought to understand the impact of biological therapies and targeted medicines for type 2 inflammation in patients with asthma.
In a recent review, Imran Howell, University of Oxford, UK, and colleagues sought to understand the impact of biological therapies and targeted medicines for type 2 inflammation in patients with asthma.
In a recent review, Imran...
12/20/2023
First Report Managed Care
News
Dairy, Gluten Show No Major Effect on MS Activity and Quality of Life
02/15/2024
Jolynn Tumolo
Dairy and gluten intake had no substantial effects on disease activity and quality of life in a retrospective study of 186 patients with multiple sclerosis (MS). Researchers published their findings online in Multiple Sclerosis Journal –...
Dairy and gluten intake had no substantial effects on disease activity and quality of life in a retrospective study of 186 patients with multiple sclerosis (MS). Researchers published their findings online in Multiple Sclerosis Journal –...
Dairy and gluten intake had no...
02/15/2024
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use